Koros C, Simitsi AM, Papagiannakis N, et al. - In the present study, the researchers sought to assess differences in serum uric acid level among Parkinson disease (PD) patients harboring mutations in the glucocerebrosidase (GBA1) gene, sporadic PD, and healthy controls followed longitudinally. The Parkinson’s Progression Markers Initiative database was used for longitudinal 2-year serum uric acid measurement data from 120 GBA-PD patients. This cohort was contrasted with 369 de novo sporadic PD patients and 195 healthy controls recruited in the same study. The GBA-PD cohort had a lower 2-year longitudinal uric acid level vs the controls, after adjustment for age, gender and BMI. In a GBA-PD cohort, this is the first study to determine serum uric acid. In GBA-PD, low serum uric acid could be a progression biomarker. However, more studies, preferably longitudinal, on the link between low serum uric acid and clinical data in GBA-PD are required. These findings are consistent with evidence from prior studies analyzing uric acid as a biomarker in other genetic forms of PD.